Answers are grounded in this paper and cite their sources.
As the number of survivors increases, improving cancer patients’ quality of life has emerged as a vital priority [1]. Fatigue, which reduces quality of life, is the most pervasive and distressing side effect reported by cancer patients, especially during treatment. Regardless of cancer type and treatment modality, nearly all patients experience fatigue during cancer treatment and nearly a third report chronic fatigue that persists for years after treatment completion [2,3]. Cancer-related fatigue (CRF) is a general term for fatigue experienced by individuals with different cancer conditions and those who are receiving or have completed the various cancer treatments. CRF is characterized by consistent physical and mental tiredness, unrelated to activity and not relieved by rest. Additionally, these symptoms can be accompanied by depression and impairment in cognition and sleep [4]. Proposed etiologic mechanisms of CRF implicate immune system dysregulation, impaired nerve conduction, neuroendocrine and neurotransmitter dysregulation, and energy depletion [5–7]. Central mechanisms proposed include disruptions in basal ganglia and frontal lobe function, hypothalamic–pituitary–adrenal axis dysfunction, and enhanced proinflammatory cytokine release affecting neuronal metabolism [8–11]. Peripherally, impaired muscle contraction, peripheral nerve conduction, and other neuromuscular abnormalities are thought to contribute to CRF [12,13]. While the potential for involvement of these diverse mechanisms has been demonstrated, no biomarker has been consistently associated with CRF in large sample studies [5,6,10,14,15]. Furthermore, although a large variety of questionnaires to evaluate CRF have been developed, there is little consensus about what outcomes define this condition, hampering comparisons between trials [3]. To facilitate comparison across studies and better understand the pathophysiological processes associated with the CRF phenotype, clear contexts surrounding the CRF experiences of patient subsets should be considered. More specific definitions of CRF that account for the various causes and manifestations of CRF can improve CRF measurement, definition, and investigation. The recently proposed National Institutes of Health Symptom Science Model proposes that a clear phenotype of symptoms can direct better understanding and discovery of potential biomarkers [16]. This editorial provides support for this approach and suggests strategies to achieve this goal.
No takes yet. Share an insight, caveat, or question.
Renner et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: